GlaxoSmithKline PLC has bowed out of the auction for Pfizer Inc.'s consumer health business – it’s a good move by the UK giant, which recently laid out a strategy that focused on growth in pharmaceuticals.
GSK Drops Out Of Auction For Pfizer's Consumer Health Unit
The acquisition of Pfizer's consumer health business, which includes big named products such as Advil painkillers and Centrum multivitamins, has proven too big and too costly for GSK investors to stomach.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.